Kiniksa Pharmaceuticals International financials
$75.73−0.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $243.6M | $214.3M | $202.1M | $180.9M | $156.8M | $137.8M | $122.5M | $112.2M | $108.6M | $79.9M | $83.4M | $67.0M |
| Gross profit | $220.0M | $193.5M | $181.2M | $160.6M | $138.2M | $119.9M | $104.6M | $92.1M | $96.3M | $69.3M | $17.3M | $58.0M |
| Gross margin | 90.3% | 90.3% | 89.6% | 88.8% | 88.1% | 87.0% | 85.4% | 82.1% | 88.7% | 86.7% | 20.7% | 86.4% |
| Operating income | $27.2M | $29.3M | $19.8M | $24.0M | $20.2M | $13.3M | -$19.3M | -$9.7M | -$117.0K | -$16.5M | $81.0K | -$10.9M |
| Net income | $25.4M | $22.6M | $14.2M | $18.4M | $17.8M | $8.5M | -$8.9M | -$12.7M | -$3.9M | -$17.7M | $25.2M | -$13.9M |
| Net margin | 10.4% | 10.5% | 7.0% | 10.2% | 11.4% | 6.2% | −7.3% | −11.3% | −3.6% | −22.2% | 30.3% | −20.7% |
| Diluted EPS | $0.30 | $0.27 | $0.17 | $0.23 | $0.23 | $0.11 | $-0.12 | $-0.18 | $-0.06 | $-0.25 | $0.33 | $-0.20 |
| EBITDA | $27.7M | $29.7M | $20.2M | $24.4M | $20.5M | $13.6M | -$18.9M | -$9.2M | $289.0K | -$16.1M | $621.0K | -$10.3M |
| Operating cash flow | $47.2M | $50.2M | $53.9M | $33.7M | $28.1M | $22.3M | $18.8M | -$2.2M | $5.2M | $4.0M | $4.3M | $17.0M |
| Free cash flow | $46.5M | $50.0M | $53.3M | $33.0M | $27.9M | $22.2M | $18.6M | -$2.2M | $5.2M | $3.9M | $4.3M | $17.0M |
| Diluted shares | 83.4M | 82.4M | 81.8M | 80.0M | 77.9M | 76.1M | 72.3M | 71.7M | 71.0M | 70.6M | 76.1M | 70.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $175.7M | $190.0M | $165.6M | $174.9M | $192.0M | $157.1M |
| Short-term investments | $350.3M | $278.1M | $248.5M | $177.2M | $115.7M | $111.2M |
| Total debt | $88.0M | $75.6M | $70.0M | $63.3M | $52.4M | $53.8M |
| Total assets | $896.1M | $825.3M | $763.6M | $712.3M | $661.1M | $599.3M |
| Total liabilities | $242.0M | $219.6M | $196.0M | $176.9M | $166.1M | $141.8M |
| Shareholders' equity | $654.1M | $605.7M | $567.6M | $535.4M | $495.0M | $457.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology